Edition:
United Kingdom

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

0.43USD
12 Jan 2018
Change (% chg)

-- (--)
Prev Close
$0.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
104,381
52-wk High
$1.24
52-wk Low
$0.30

Latest Key Developments (Source: Significant Developments)

Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Heat Biologics Inc ::SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL.HEAT BIOLOGICS - RECEIVED WRITTEN RESPONSES FROM U.S. FDA REGARDING HS-110 TRIAL DESIGN FOR TREATMENT OF NON-SMALL CELL LUNG CANCER.HEAT BIOLOGICS - FDA AGREED THAT TRIAL DESIGNS, BOTH SINGLE-ARM AND CONTROLLED, WOULD BE APPROPRIATE TO SUPPORT REGISTRATIONAL TRIAL OF HS-110.HEAT BIOLOGICS - TRIAL DESIGN DETAILS AND NEXT STEPS EXPECTED TO BE ANNOUNCED FOLLOWING READ-OUT OF PHASE 2 DATA, ANTICIPATED IN 2H 2018.  Full Article

Heat Biologics reports Q3 net loss attributable to Heat $0.06 per basic and diluted share‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Heat Biologics Inc :Heat Biologics Inc - qtrly net loss attributable to Heat for the third quarter of 2017 was $0.06 per basic and diluted share‍​.Heat Biologics Inc - ‍cash and cash equivalents totaled approximately $4.3 million, as of September 30, 2017​.  Full Article

Heat Biologics Inc files for mixed shelf of up to $50 million ‍​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Heat Biologics Inc :Heat Biologics Inc files for mixed shelf of up to $50 million – SEC filing ‍​.  Full Article

Heat Biologics substantially reduces debt and reports proceeds of approximately $2.8 million
Friday, 7 Oct 2016 

Heat Biologics Inc : Heat Biologics substantially reduces debt and reports proceeds of approximately $2.8 million year to-date from the exercise of warrants .Says that it has paid down $1.5 million on its commercial loan following recent exercise of warrants.  Full Article

Heat Biologics qtrly loss per share $0.17
Monday, 15 Aug 2016 

Heat Biologics Inc : Heat biologics provides corporate update and reports second quarter 2016 financial results .Qtrly loss per share $0.17.  Full Article

Heat Biologics announces proposed public offering of common stock
Thursday, 21 Jul 2016 

Heat Biologics Inc :Announces proposed public offering of common stock.  Full Article

Heat Biologics presents a poster on its HS-110/Nivolumab
Monday, 6 Jun 2016 

Heat Biologics Inc : Additional data illustrates clinical and immune response correlation .Presents A Poster On Its Hs-110/nivolumab combination phase 1b non-small cell lung cancer trial at ASCO annual meeting.  Full Article

Heat Biologics Q1 loss per share $0.50
Wednesday, 11 May 2016 

Heat Biologics Inc : Qtrly loss per share $0.50 .Heat Biologics reports first quarter 2016 financial results.  Full Article

Heat Biologics Inc cuts 22 pct of workforce - Reuters News
Thursday, 7 Apr 2016 

Heat Biologics Inc:Saving measures and focused corporate strategy to achieve important clinical milestones.Cost-Saving measures include reduction in compensation for remaining leadership team.Cost-Saving measures include a workforce reduction of approximately 22% of company's headcount.Also announced voluntary resignation of two members from its board of directors.Will further decrease operating expenses by advancing only 8 patients enrolled in phase 1b clinical trial evaluating hs-110.Intends to focus resources on near-term milestones for hs-410 and hs-110, both of which are expecting topline data in q4 of 2016.  Full Article

FDA lifts Heat Biologics Inc partial clinical hold
Wednesday, 10 Feb 2016 

Heat Biologics Inc:FDA lifts Heat Biologics partial clinical hold.Says FDA lifts partial clinical hold on phase 2 trial evaluating hs-410 either alone or in combination with standard of care bcg.Says HEAT will resume patient enrollment on hs-410.Says clinical timelines remain materially unchanged with topline data expected in the fourth quarter of 2016.  Full Article